All GLG News Analyses Filed Under: Cardiology

Physicians have several possible conclusions that can be taken; These include: - the trial is flawed - the selection of patients with much less CIMT than previous trials such as ASAP and ARBITER flaws the study -  the failure to meet the trial endpoint is only a surrogate and clinical trial data...

At present despite the statins we have, many do not reach goal. In fact. it may be that that goal is not adequate as we have still a major issue with cardiovascular disease. This product may prove to be a further advance along this line.

This may be a better drug than plavix, but it also has more serious bleeding problems. It will likely be approved, but with restictions if it is.

vWF is one of a number of attractive antiplatelet targets which include P2Y112, GIIb/IIIa, to name a few. Currently Medicines Company's Cangrelor, a small molecule against P2Y12 is quite far along in development.  In addition, Archemix just published results of its Phase I trial with its anti-vWF...

Drug will target early key adhesion events that facilitate platelet adherence to exposed subendothelium after injury- may have significant influence in blocking subsequent events leading to thrombosis; however, it will be interesting to see if this drug class will increase bleeding or reduce wound...

A novel antibody, ALX-0081, that is well tolerated nd is directed against von Willebrand Factor (anti-vWF), that is strongly implicated in taking part in acute coronary events and conclusively responsible for the disastrous outcomes of thrombotic thrombocytopenic purpura (TTP).

Niacin is the most potent approved HDL-raising agent with evidence for cardiovascular benefit. Flush is the limiting side-effect. EPA (a major component of omega 3 fish oil) decreases triglycerides and may have antiarrhythmic properties.

This is great news for Canada.  This is the first new drug approved for the treatment of acute heart failure since 1989, when milrinone was approved.  Nesiritide was approved in the United States in 2001.  Since then, it has proven to be of great benefit in patients with acute heart failure,...

so far we have been restricted to the use of vasopressor in the perioperative setting with its adverse consequences on microvasculature particularly renal.with the availability of natrecor this category of patients where peripheral vasoconstriction is undesirable ,will immensely benefit. weaning off...

How will the FDA rule? What are the potential public health benefits? Are there risks of OTC statins?  Watching closely, will be Glaxo Smithkline (GSK), which will market OTC Mevacor. Approval could impact sales of Pfizer's Lipitor and other statins made by pharma's including AstraZeneca, Novartis...